Current
Neuro-Oncology


Volume 24 Number 11
15 June 2022


Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 11, 15 June






Reiner AS, Lobaugh SM, Gonen S, Diamond EL, Panageas KS.
A Population-Based Study of Treatment and Survival in Older Glioma Patients.
JNCI Cancer Spectr. 2022 Feb 9, 2022 Feb;6(1):pkac010
. doi: 10.1093/jncics/pkac010. PMID: 35699501. Retrospective analysis.




Galanis E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU, Campian J, Giannini C, Buckner JC, Wen PY.
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).
Neurooncol Adv. 2022 Apr 4, 2022 Jan-Dec;4(1):vdac041
. doi: 10.1093/noajnl/vdac041. PMID: 35664553. Phase1-2 clinical trial.




Grogan PT, Deming DA, Helgager J, Ruszkiewicz T, Baskaya MK, Howard SP, Robins HI.
Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma.
Neurooncol Adv. 2022 Apr 13, 2022 Jan-Dec;4(1):vdac046
. doi: 10.1093/noajnl/vdac046. PMID: 35673607. Case report.




Sangrador-Deitos MV, Villanueva-Castro E, Marian-Magaña R, Rodríguez-Hernández LA, Guinto-Nishimura GY, Gómez-Amador JL, Corona-Vázquez T, Wegman-Ostorozky T, Mejia S.
Carboplatin Plus Vincristine as an Alternative Chemotherapeutic Scheme in Patients With Glioblastoma.
Cureus. 2022 Apr 25;14(4):e24467
. doi: 10.7759/cureus.24467. PMID: 35637821. Retrospective analysis.




Lin MS, Lee CH, Chen SY, Shen CC.
Collision brain tumor with atypical meningioma and glioblastoma: Case report.
Int J Surg Case Rep. 2022 May 4, 2022 May;94:107137
. doi: 10.1016/j.ijscr.2022.107137. PMID: 35658305. Case report.




Seliger C, Nürnberg C, Wick W, Wick A.
Lung toxicity of lomustine in the treatment of progressive gliomas.
Neurooncol Adv. 2022 May 10, 2022 Jan-Dec;4(1):vdac068
. doi: 10.1093/noajnl/vdac068. PMID: 35664555. Retrospective analysis.



*

Pauletto G, Nilo A, Lettieri C, Verriello L, Tomasino B, Gigli GL, Skrap M, Ius T.
Pre- and Post-surgical Poor Seizure Control as Hallmark of Malignant Progression in Patients With Glioma?
Front Neurol. 2022 May 16;13:890857
. doi: 10.3389/fneur.2022.890857. PMID: 35651351. Retrospective analysis.



*

Chi X, Wang Y, Li C, Huang X, Gao H, Zhang Y, Ji N.
Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma.
Front Oncol. 2022 May 18;12:877190
. doi: 10.3389/fonc.2022.877190. PMID: 35664765. Phase 1 clinical trial.



*

Liu CA, Harn HJ, Chen KP, Lee JH, Lin SZ, Chiu TL.
Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM.
J Oncol. 2022 May 18;2022:3236058
. doi: 10.1155/2022/3236058. PMID: 35646111. Case report.




Teng C, Zhu Y, Li Y, Dai L, Pan Z, Wanggou S, Li X.
Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Front Immunol. 2022 May 23;13:899710
. doi: 10.3389/fimmu.2022.899710. PMID: 35677036. Prediction tool.



*

Ustjanzew A, Sencio V, Trottein F, Faber J, Sandhoff R, Paret C.
Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance.
Int J Mol Sci. 2022 May 24;23(11):5896
. doi: 10.3390/ijms23115896. PMID: 35682578. Laboratory investigation.




de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
Neuro Oncol. 2022 May 25:noac139
. Doi: 10.1093/neuonc/noac139. PMID: 35639513. Phase 1b/2 clinical trial.




Klingenschmid J, Krigers A, Kerschbaumer J, Thomé C, Pinggera D, Freyschlag CF.
Surgical Management of Malignant Glioma in the Elderly.
Front Oncol. 2022 May 26;12:900382
. doi: 10.3389/fonc.2022.900382. PMID: 35692808. Retrospective analysis.




Weiss Lucas C, Faymonville AM, Loução R, Schroeter C, Nettekoven C, Oros-Peusquens AM, Langen KJ, Shah NJ, Stoffels G, Neuschmelting V, Blau T, Neuschmelting H, Hellmich M, Kocher M, Grefkes C, Goldbrunner R.
Surgery of Motor Eloquent Glioblastoma Guided by TMS-Informed Tractography: Driving Resection Completeness Towards Prolonged Survival.
Front Oncol. 2022 May 27;12:874631
. doi: 10.3389/fonc.2022.874631. PMID: 35692752. Prospective study.




Oberheim-Bush NA, Shi W, McDermott MW, Grote A, Stindl J, Lustgarten L.
The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts.
J Neurooncol. 2022 May 31
. doi: 10.1007/s11060-022-04033-4. PMID: 35639236. Retrospective analysis;




Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW; GLASS Consortium.
Glioma progression is shaped by genetic evolution and microenvironment interactions.
Cell. 2022 May 31, 2022 Jun 9;185(12):2184-2199.e16
. doi: 10.1016/j.cell.2022.04.038. PMID: 35649412. Laboratory investigation;




Villani V, Prosperini L, Lecce M, Tanzilli A, Farneti A, Benincasa D, Telera S, Marucci L, Piludu F, Pace A.
Recurrent glioblastoma: which treatment? A real-world study from the Neuro-oncology Unit "Regina Elena" National Cancer Institute.
Neurol Sci. 2022 May 31. doi: 10.1007/s10072-022-06172-y
. PMID: 35641731. Retrospective analysis;




Ruggi A, Melchionda F, Sardi I, Pavone R, Meneghello L, Kitanovski L, Zaletel LZ, Farace P, Zucchelli M, Scagnet M, Toni F, Righetto R, Cianchetti M, Prete A, Greto D, Cammelli S, Morganti AG, Rombi B.
Toxicity and Clinical Results after Proton Therapy for Pediatric Medulloblastoma: A Multi-Centric Retrospective Study.
Cancers (Basel). 2022 Jun 1;14(11):2747
. doi: 10.3390/cancers14112747. PMID: 35681727. Retrospective analysis.




Gupta T, Pervez S, Dasgupta A, Chatterjee A, Epari S, Chinnaswamy G, Jalali R.
Omission of upfront craniospinal irradiation in patients with low-risk WNT-pathway medulloblastoma is associated with unacceptably high risk of neuraxial failure.
Clin Cancer Res. 2022 Jun 2:clincanres.0758.2022-3-10 10:06:35.290
. doi: 10.1158/1078-0432.CCR-22-0758? PMID: 35653134. Prospective study;



*

Duval T, Lotterie JA, Lemarie A, Delmas C, Tensaouti F, Moyal EC, Lubrano V.
Glioblastoma Stem-like Cell Detection Using Perfusion and Diffusion MRI.
Cancers (Basel). 2022 Jun 4;14(11):2803
. doi: 10.3390/cancers14112803. PMID: 35681782. Prospective study.




Cucchiara F, Luci G, Giannini N, Giorgi FS, Orlandi P, Banchi M, Di Paolo A, Pasqualetti F, Danesi R, Bocci G.
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Pharmacol Res. 2022 Jun 6;181:106290
. doi: 10.1016/j.phrs.2022.106290. PMID: 35680010. Retrospective analysis;




Saraf A, Yock TI, Niemierko A, Oh KS, Curry WT, Butler WE, Arrillaga-Romany I, Ebb DH, Tarbell NJ, MacDonald S, Loeffler JS, Shih HA.
Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience.
Neuro Oncol. 2022 Jun 7:noac126
. doi: 10.1093/neuonc/noac126. PMID: 35671386. Retrospective analysis.



*

Ramos-Fresnedo A, Domingo RA, Perez-Vega C, Pullen MW, Akinduro OO, Almeida JP, Jentoft ME, Bendok BR, Chaichana KL, Trifiletti DM, Burns TC, Porter AB, Kizilbash SH, Middlebrooks EH, Quiñones-Hinojosa A, Sherman WJ.
The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study.
J Neurooncol. 2022 Jun 14
. doi: 10.1007/s11060-022-04040-5. PMID: 35699848. Retrospective analysis;




Drljača J, Popović A, Bulajić D, Stilinović N, Vidičević Novaković S, Sekulić S, Milenković I, Ninković S, Ljubković M, Čapo I.
Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.
CNS Neurosci Ther. 2022 Jun 15
. doi: 10.1111/cns.13889. PMID: 35703405. Laboratory investigation.




Weller J, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Schlegel U, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Pietsch T, Tzaridis T, Zeyen T, Borger V, Güresir E, Vatter H, Herrlinger U, Schneider M.
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
J Neurooncol. 2022 Jun 15
. doi: 10.1007/s11060-022-04046-z. PMID: 35704157. Phase 2 and 3 clinical trials.









□□□